| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |